Oct 5 (Reuters) - US health officials are advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder, the FDA ...
Local 10 News also reported that in February 2026, Miami Beach SWAT and undercover detectives raided a 76th Street apartment ...
Newspoint on MSN
MPSC: State Services Main Exam scheduled for October 3 postponed; Commission's major decision amidst paper leak controversy
The Maharashtra Public Service Commission (MPSC) has postponed the State Services Main Examination 2026. This exam was ...
The FDA has issued a final rule that would remove references to animal studies in its drug safety regulations, as part of a ...
The agency plans to fast-track applications for several psychedelics, but it must also create a set of rules about who can take and administer them and in what settings.
DEA Chief Administrative Law Judge Derek Julius on Tuesday stayed pending proceedings on marijuana rescheduling after a ...
Revolution Medicines trades at 18x–58x projected 2027 U.S. revenue scenarios, leading to a Hold rating despite robust ...
Lenacapavir is a long-acting antiretroviral medicine that has introduced a fundamentally different approach to HIV prevention ...
Father and Son Face Federal Drug Charges After Bank Records Tie Ole Miss Student to Oxford Vape Shop
Two Oxford men face federal kratom derivative charges in an Ole Miss death probe. See what is alleged, what is unproven, and ...
A phase 2 clinical trial has delivered some of the most striking results yet reported in early-stage classical Hodgkin ...
Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results